Introduction
============

Binaural hearing enables a person to differentiate a sound of interest from background noise and localize sounds by using various effects of binaural hearing such as: summation, head shadow, and squelch effect ([@B3]; [@B16]; [@B1]; [@B19]). There is a wealth of scientific evidence advocating bilateral cochlear implantation (BiCI) over unilateral cochlear implantation (UCI), highlighting that input in both ears instead of one holds evident advantages. In recent years, the difference between BiCI and UCI in adults with severe-to-profound sensorineural hearing loss (SNHL) has been studied thoroughly ([@B2]; [@B10]; [@B31]) evidencing a benefit of BiCI over UCI on speech perception tasks in noise, localization of sounds abilities and quality of hearing (QoH) and quality of life (QoL) improvement. Nonetheless, we believe that a lack of high level concrete evidence such as that derived from a randomized controlled trial (RCT) is much needed to elucidate the BiCI advantage over UCI. Many health care systems such as that in the Netherlands do not reimburse the second cochlear implant in adults due to insufficient proof of societal benefit (cost-utility).

Thus far, there is a lack of overall consensus on whether bilateral cochlear implants should be implanted simultaneously or sequentially. Observational studies have demonstrated advantages of simultaneous BiCI (simBiCI) over UCI as well as sequential BiCI (seqBiCI) over UCI, but no comparative studies exist on the difference between simBiCI versus seqBiCI.

In 2016, our research group published the first results of a RCT comparing outcomes of BiCI to UCI (with or without contralateral hearing aid (HA), e.g., bimodal). It showed conclusive evidence that BiCI patients have superior results over UCI patients on speech perception in noise and localization of sounds using various behavioral and self-reported outcome measures ([@B28]; [@B32]). UCI patients in that study received a second CI after 2 years of unilateral CI use, enabling researchers to not only investigate the difference between BiCI and UCI (and bimodal), but also evaluate performances between simultaneous BiCI (simBiCI) and sequential BiCI (UCI/BiCI). The results of this cross-sectional comparison demonstrated comparable performances in both groups for almost all outcome measures after 1 year of BiCI experience ([@B13]).

It has been reported that short and long-term performance of CI recipients often varies. To date, investigations evaluating long-term outcomes after simBiCI compared with seqBiCI in adult patients are lacking. In the current paper, we present long-term results of 4 years of follow-up using longitudinal analyses that evaluates behavioral outcomes (speech perception and localization), self-reported outcomes (QoL, QoH, and tinnitus outcomes), as well as complications that occurred during the course of this trial.

Materials and Methods {#s1}
=====================

Ethical Considerations
----------------------

This study was approved by the Human Ethics Committees of the Academic Medical Center Amsterdam and consecutively tested for local applicability at all participating centers (University Medical Centers of Utrecht, Maastricht, Nijmegen, Leiden, and Groningen) (NL2466001808), registered in the Dutch Trial Register (NTR1722) and conducted according to the Declaration of Helsinki. Written informed consent was obtained from all participants ([@B28]; [@B32]; [@B13]).

Study Design and Participants
-----------------------------

This RCT compares behavioral and self-reported outcomes of simBiCI to seqBiCI (UCI/seqBiCI group) in adults with severe-to-profound bilateral postlingual SNHL longitudinally during a 4-year follow-up. Data were reported according to the CONSORT statement ([@B26]).

Between December 2009 and September 2012, all adults eligible for cochlear implantation by the clinical teams of University Medical Centers Utrecht, Maastricht, Nijmegen, Groningen, and Leiden were assessed for this study's inclusion and exclusion criteria ([@B28]; [@B32]; [@B13]). The inclusion criteria were: age: 18--70 years; postlingual onset of SNHL; unaided pure-tone average (PTA, mean of 500, 1,000, 2,000 Hertz) ≥70 dB in both ears; duration of severe-to-profound SNHL \< 20 years in each ear and a difference in duration of deafness between both ears \< 10 years; marginal benefit of HAs, defined as an aided consonant vowel consonant (CVC) phoneme score for both ears of ≤50% at 65 dB sound pressure level (SPL); Dutch as native language; willingness and ability to participate in all scheduled procedures; general health allowing general anesthesia for the duration of potential simBiCI; Dutch health insurance coverage; and agreement to be implanted with Advanced Bionics^®^ implants. The exclusion criteria were: previous CI; abnormal cochlear anatomy; and chronic ear infections; [@B32]; [@B13]).

Intervention
------------

After giving written informed consent and undergoing baseline evaluations, patients were randomly allocated to simBiCI or seqBiCI (UCI/seqBiCI group). It is important to note that in the Netherlands, BiCI is not yet reimbursed in adults. The UCI/seqBiCI group had an inter-implant interval of 2 years ([Figure 1](#F1){ref-type="fig"}). Using a web-based randomization program, a block randomization per center strategy was used to obtain an equal distribution between simBiCI and UCI/seqBiCI groups in all centers ([@B28]; [@B32]; [@B13]). All participants received an Advanced Bionics HiRes90K^®^ implant (Advanced Bionics, Sylmar, CA, United States) coupled with a Harmony processor with HiRes/HiRes120 processing strategies. Participants in the UCI/seqBiCI group were encouraged to keep using a contralateral HA in the first 2 years before sequential implantation.

![Flowchart of enrollment. simBiCI, simultaneous bilateral cochlear implantation; UCI/seqBiCI, unilateral/sequential bilateral cochlear implantation.](fnins-13-00054-g001){#F1}

Follow-Up
---------

All outcome measures, unless otherwise mentioned below, were evaluated at baseline and after 1, 2, 3, and 4 years of follow-up ([Figure 1](#F1){ref-type="fig"}). The follow up visits lasting approximately 2--2.5 h entailed filling respective questionnaires and behavioral testing. Participants and observers were not blinded for the intervention during evaluations due to the nature of the intervention.

Behavioral Outcome Measures
---------------------------

Behavioral outcomes included speech perception in noise coming from a source directly in front of the patient (speech and noise from a target located in front of the listener at 0 degrees azimuth), speech intelligibility-in-noise from spatially separated sources (SISSS), localization capabilities and speech perception in quiet. All behavioral outcomes were conducted using the AB-York Crescent of Sound set-up, with horizontally placed loudspeakers in a semicircle around the participant ([@B27]). Numbers representing the loudspeaker were shown on monitors below the loudspeakers. In the UCI/seqBiCI group, data were obtained from the 'participant's preferred situation' for the tests conducted before the second implantation. The preferred situation was determined as the situation in which patients performed best, either using the CI (CI1) only or the bimodal condition (CI1 + contralateral HA). In the simBiCI group and for the latter two test moments in the UCI/seqBiCI group, data were gathered from tests performed with both cochlear implants switched on ([@B27]; [@B12]).

### Speech Perception in Noise

The primary outcome was speech perception in noise coming from a source directly in front of the patient, measured with the Utrecht-Sentence Test with Adaptive Randomized Roving levels. Dutch VU-98 were presented in noise at 65, 70, or 75 dB SPL (randomly selected). The number of keywords correctly repeated per sentence was scored. Sentences were presented with an initial signal-to-noise ratio (SNR) of +20 dB. If a sentence was scored correct (2 of 3 or 3 of 5 keywords correct), the SNR of the next sentence was decreased by increasing the noise level. Contrarily, if a sentence was scored as incorrect, the SNR was increased. The SNR was altered in steps of 10, 5 and 2.5 dB. The mean SNR of the last 10 sentences was calculated, resulting in a speech reception threshold in noise (SRTn) ([@B27], [@B28]; [@B12]). A lower score reflects better speech perception. An SRTn of 30 dB was considered speech perception in relative silence and was used as a cut-off point for all scores above 30 dB ([@B12]).

In the SISSS, also resulting in an SRTn, sentences were presented from 60° azimuth to the left of the patient and noise from 60° azimuth to the right of the patient (S-60 N+60) and vice versa (S+60 N-60) ([@B12]). When sounds come from different directions, participants usually have a *best performance situation (BPS)* and a *worst performance situation (WPS)*. A participant's *BPS* was determined as the situation where speech was presented to the ear with the lowest SNR and noise to the ear with the highest SNR. In a participant's *WPS*, speech and noise originate from the opposite sides. In the UCI/seqBiCI group before CI2, the *BPS* was defined as the situation in which the target speech was presented to the implanted ear and noise to the non-implanted ear ([@B12], [@B13]; [@B28]; [@B32]).

### Localization Capabilities

For the localization test, participants were instructed to look at the loudspeaker placed directly in front during the entire procedure. A camera was placed in front of the participant and a deviation of the head of the participant was corrected by the observer. Thirty short phrases ("Hello, what's this?") were presented randomly at 60, 65, or 70 dB SPL from one of the loudspeakers. The results were percentage of correct responses. The test was performed in three localization conditions: 15° angle azimuth between five loudspeakers, 30° angle azimuth between five loudspeakers, and 60° angle azimuth between three loudspeakers ([@B28]; [@B32]; [@B13]).

### Speech Perception in Quiet

Speech perception in quiet from a loudspeaker in front of the patient was measured using the standard Dutch CVC test, resulting in a maximum percentage correctly repeated phonemes. This was the only behavioral test which was evaluated at baseline, before randomization.

Self-Reported Outcome Measures
------------------------------

### Quality of Life

The QoL questionnaires included the EuroQol five-dimensional questionnaire (EQ-5D), the Health Utilities Index mark 3 (HUI3), a Visual Analog Scale (VAS) on general health, and the Time Trade-off (TTO) ([@B30]; [@B5]; [@B7]; [@B15]). The EQ-5D contains a thermometer indicating general health state and five dimensions of QoL: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The result is a single index value for health status: a utility score ranging from -0.33 to 1.00 ([@B5]; [@B15]; [@B24]). The HUI3 consists of eight elements of health status. The result is a utility score between -0.36 and 1.00 ([@B7]; [@B24]). The VAS on general health contains a thermometer for general QoL, which results in a utility score between 0 and 1 ([@B24]). The TTO is an instrument asking participants whether they are willing to trade expected life years for perfect hearing. The utility is calculated as: utility = (life expectancy -- number of years a participant would trade)/life expectancy ([@B28]). This question needs good instruction, therefore, it was decided not to let participants answer it independently preoperatively. However, at the 1-,2-,3- and 4-year follow-up moments this information was gathered. For all QoL outcomes, a higher score reflects a better QoL.

### Quality of Hearing

The QoH questionnaires included the VAS on hearing, the Speech, Spatial and Qualities of Hearing Scale (SSQ) and the Nijmegen Cochlear Implant Questionnaire (NCIQ) ([@B11]; [@B9]). The VAS on hearing contains a thermometer for hearing, which results in a score between 0 and 1 ([@B24]). The SSQ consists of three subdomains. The SSQ1 comprises questions on speech understanding in quiet, in background noise, in reverberant environments and on the telephone. The SSQ2 comprises questions on spatial hearing; identifying directions of sounds and distance approximation, and the SSQ3 comprises questions on the QoH ([@B9]). The results are three subdomain scores ranging from 0 to 10 ([@B9]; [@B23]). The NCIQ contains six subdomains of hearing: (1) Basic sound perception, (2) Advanced sound perception (in difficult daily listening situations or background noise), (3) Speech production, (4) Self-esteem, (5) Activity limitations, (6) Social interaction ([@B11]). The results are subdomain scores ranging from 0 to 100 ([@B11]; [@B23]). As this questionnaire is specifically designed for the evaluation after cochlear implantation, this questionnaire was not administered at baseline. For all QoH outcomes, a higher score reflects a greater ability.

### Tinnitus

The tinnitus questionnaires included the Tinnitus Handicap Inventory (THI) and Tinnitus Questionnaire (TQ) ([@B20]; [@B17]). The THI is a questionnaire regarding tinnitus handicap in daily life. The questionnaire comprises a 12-item functional subscale, an 8-item emotional subscale and a 5-item catastrophic subscale ([@B20]; [@B17]; [@B22]). The TQ consists of 52 questions on emotional and cognitive distress, intrusiveness, auditory perceptual difficulties, sleep disturbance and somatic complaints ([@B18]). Both tinnitus questionnaires were administered to all participants, but could only be completed when a participant experienced tinnitus.

Sample Size Calculation
-----------------------

Sample size was calculated before the start of the trial using a *T*-test analysis of the primary outcome measure. Fourteen participants in each group were needed to detect a clinically relevant difference of 3 dB in SRTn between groups on the speech perception-in-noise coming from a source in front of the participant test with a standard deviation of 3 dB, an alpha of 0.05 and a power of 80%. Five additional subjects were included per group to compensate for any potential unexpected loss to follow-up ([@B28]; [@B32]; [@B13]).

Missing Data and Loss to Follow-Up
----------------------------------

In case participants were lost to follow-up, analyses were performed with (intention to treat) and without these missing data as a sensitivity analysis.

Statistical Analysis
--------------------

Prior to analysis, all data were double-checked by two researchers independently. Patient characteristics were presented as counts, percentages, and medians with interquartile ranges (IQRs).

All outcome measures were analyzed longitudinally (follow-up points 1, 2, 3, and 4 years) via a linear regression analysis with an autoregressive residual covariance matrix (generalized estimating equations type, using a maximum likelihood estimation method). The tinnitus outcomes were analyzed longitudinally via a logistic regression analysis with an autoregressive residual covariance matrix (generalized estimating equations type), as the outcome was dichotomized: the presence of tinnitus burden (yes or no). A participant was considered to experience tinnitus burden when a score higher than 0 was reached on either of the questionnaires.

All models included time (as a categorical variable), group (simBiCI versus UCI/seqBiCI), the interaction between time and group (to study whether the course of scores differed between the study groups) and baseline score of the particular outcome (to adjust for possible baseline differences). Since the TTO and NCIQ were not administered at baseline, the VAS on health and VAS on hearing scores were used as baseline scores. For the speech perception-in-noise and localization tests the CVC phoneme score was used. HA use (yes/no) at baseline (before the study) was the only variable which differed significantly between groups ([@B28]; [@B32]; [@B13]) and for that reason, this variable was added to all models to verify whether it was a possible confounder. Sex and age may have been related to some of the outcomes discussed in this manuscript. If so, sex and age would have also been related to the baseline outcomes. Since we corrected for baseline outcomes, no additional corrections for sex and age were performed. Residuals of the final linear models were checked for normality and showed a normal distribution. To visualize the course of all behavioral and self-reported outcomes for both study groups, all outcome measures were graphed, presenting mean outcome values with standard deviations.

A *p*-value \< 0.05 was considered statistically significant. The regression models were generated in SPSS version 22.0 whereas the residue analyses were performed in SAS version 9.4.

Results
=======

Participant Characteristics
---------------------------

Between December 2009 and September 2012, 512 patients were assessed for eligibility. Forty participants were randomized and 19 participants were included in each group ([Figure 1](#F1){ref-type="fig"}). Characteristics of participants are described in [Table 1](#T1){ref-type="table"} ([@B28]; [@B32]; [@B13]). As previously mentioned, the groups were similar at baseline except for the number of participants using a HA (19 vs. 15).

###### 

Characteristics of participants at time of inclusion in the study.

                                            UCI/SeqBiCI Median \[IQR\]   SimBiCI Median \[IQR\]
  ----------------------------------------- ---------------------------- ------------------------
  Male:Female                               11:08                        08:11
  Age at inclusion (years)                  54 \[43--64\]                52 \[36--63\]
  Duration of severe HL AD (years)          17 \[9--33\]                 16 \[11--25\]
  Duration of severe HL AS (years)          18 \[9--35\]                 16 \[11--25\]
  First CI, right:left                      6:13                         17:2
  PTA AD (dB)                               106 \[94--111\]              106 \[89--119\]
  PTA AS (dB)                               108 \[93--114\]              108 89--120\]
  CVC phoneme score with hearing aids (%)   44 \[29--56\]                48 \[24--63\]
  Hearing aid use year 0, yes:no            19:0                         15:4
  Hearing aid use year 1, yes:no            12:7                         Not applicable
  Hearing aid use year 2, yes:no            13:5 (1 LTFU)                Not applicable
  Treatment hospital                                                     
  Utrecht                                   11                           8
  Maastricht                                4                            5
  Nijmegen                                  2                            3
  Leiden                                    1                            2
  Groningen                                 1                            1
  Cause of deafness                                                      
  Hereditary                                7                            9
  Unknown and progressive                   9                            6
  Sudden deafness                           0                            2
  Head trauma                               0                            1
  Meningitis                                2                            0
  Rhesus antagonism                         1                            0
  Sound exposure                            0                            1
                                                                         

BiCI, bilateral cochlear implantation; yrs, years; UCI, unilateral cochlear implantation; Sim, simultaneous; Seq, sequential; AD, auricus dexter; AS, auriculus sinistra; PTA, pure tone average over 1, 2, and 4 kilohertz; CVC, consonant vowel consonant; CI, cochlear implant; LTFU, lost to follow-up; Hz, hertz; IQR, interquartile ranges.

Missing Data and Loss to Follow-Up
----------------------------------

During the second and third year of follow-up, two participants in the UCI/seqBiCI group withdrew for personal reasons. A third participant was excluded from the UCI/seqBiCI group because of poor performance with the first implant. This participant appeared to have a hearing loss due to rhesus antagonism and was expected not to benefit from a second CI because of this central cause of deafness ([Figure 1](#F1){ref-type="fig"}) ([@B28]; [@B32]; [@B13]).

At year 1, the 15° localization results were missing in one participant in the simBiCI group. A cut-off of 30 dB for speech perception scores was used for one participant in each group. At year 3, the results of the VAS health and hearing were missing in one participant in the simBiCI group and the TTO was missing for another participant in this group. At year 4, the EQ-5D was missing for one participant in the simBiCI group and TTO was missing for another participant in this group.

Behavioral Outcomes
-------------------

[Figure 2](#F2){ref-type="fig"} shows all behavioral outcomes during the 4 years follow-up for both study groups. Group differences, course per group and difference between follow-up moments per group were analyzed using the previously mentioned linear regression analysis with an autoregressive residual covariance matrix. In the UCI/seqBiCI group, 10 and 11 out of 16 participants used a contralateral HA at year 1 and year 2 respectively.

![Behavioral outcomes on hearing: a 4-year follow-up. Scores are presented in mean values with an error bar representing the standard deviation. SISSS, speech intelligibility-in-noise from spatially separated sources; WPS, worst performance situation; BPS, best performance situation; CVC, consonant vowel consonant; yr, year; CI, cochlear implant; SimBiCI, simultaneous bilateral cochlear implantation; UCI/seqBiCI, unilateral cochlear implantation/sequential bilateral cochlear implantation group. To improve readability, the results of both groups are presented interleaved, yet follow-up moments were similar in both groups.](fnins-13-00054-g002){#F2}

### Speech Perception in Noise

Speech perception in noise coming from a source in front of the participant did not differ significantly between UCI/seqBiCI and simBiCI over time (1.99 dB \[-1.55 -- 5.53\], *p* = 0.265) ([Table 2](#T2){ref-type="table"}). The course of the SRTn did not differ significantly between the two groups and for both groups the SRTns remained stable over time.

###### 

Results from a linear regression analysis with an autoregressive residual covariance matrix (generalized estimating equations type) for all objective outcomes.

                                                           Parameter      Mean     SD     Lower bound 95% CI   Upper bound 95% CI   *P*-value
  -------------------------------------------------------- -------------- -------- ------ -------------------- -------------------- --------------
  Speech perception in noise from directly in front (dB)   Treatment      1.99     1.77   -1.55                5.53                 0.265
                                                           Year 2         0.49     1.22   -1.91                2.91                 0.686
                                                           Year 3         -0.38    1.05   -2.45                1.69                 0.718
                                                           Year 4         -0.81    0.80   -2.41                0.78                 0.314
                                                           Seq × year 2   -0.18    1.74   -3.63                3.26                 0.916
                                                           Seq × year 3   -0.23    1.51   -3.23                2.76                 0.877
                                                           Seq × year 4   0.02     1.16   -2.27                2.32                 0.986
                                                           CVC baseline   -0.06    0.03   -0.12                0.01                 0.076
  SISSS: WPS (dB)                                          Treatment      8.70     2.37   3.96                 13.44                **\<0.001**
                                                           Year 2         1.51     1.76   -1.97                4.99                 0.391
                                                           Year 3         -0.41    1.53   -3.43                2.61                 0.787
                                                           Year 4         -0.58    1.19   -2.94                1.77                 0.623
                                                           Seq × year 2   -1.50    2.51   -6.47                3.47                 0.551
                                                           Seq × year 3   -6.83    2.21   -11.20               -2.45                **0.002**
                                                           Seq × year 4   -7.06    1.71   -10.44               -3.67                **\<0.0001**
                                                           CVC baseline   -0.07    0.04   -0.15                0.02                 0.113
  SISSS: BPS (dB)                                          Treatment      0.79     1.96   -3.14                4.72                 0.688
                                                           Year 2         -1.07    1.40   -3.84                1.70                 0.447
                                                           Year 3         -2.60    1.22   -5.01                0.19                 **0.035**
                                                           Year 4         -2.68    0.95   -4.56                -0.80                **0.006**
                                                           Seq × year 2   0.34     2.00   -3.62                4.29                 0.866
                                                           Seq × year 3   0.48     1.76   -3.01                3.97                 0.786
                                                           Seq × year 4   0.60     1.37   -3.31                2.11                 0.663
                                                           CVC baseline   -0.012   0.04   -0.20                -0.03                **0.009**
                                                           HA use         7.05     3.42   0.10                 14.00                **0.047**
  Localization, 15° (% correct)                            Treatment      -27.87   5.01   -37.80               -17.94               **\<0.0001**
                                                           Year 2         -3.98    4.81   -13.50               5.54                 0.410
                                                           Year 3         3.21     4.54   -5.77                12.19                0.481
                                                           Year 4         9.09     3.96   1.23                 16.94                **0.024**
                                                           Seq × year 2   1.12     6.82   -12.39               14.60                0.870
                                                           Seq × year 3   19.64    6.53   6.72                 32.56                **0.003**
                                                           Seq × year 4   17.85    5.63   6.69                 29.01                **0.002**
                                                           CVC baseline   0.05     0.07   -0.09                0.19                 0.493
  Localization, 30° (% correct)                            Treatment      -41.09   4.56   -50.12               -32.06               **\<0.0001**
                                                           Year 2         -5.45    4.36   -14.06               3.16                 0.213
                                                           Year 3         -1.53    4.09   -9.63                6.56                 0.709
                                                           Year 4         -2.25    3.53   -9.27                4.77                 0.526
                                                           Seq × year 2   3.24     6.21   -9.02                15.51                0.602
                                                           Seq × year 3   34.20    5.93   22.48                45.92                **\<0.0001**
                                                           Seq × year 4   35.73    5.07   25.67                45.79                **\<0.0001**
                                                           CVC baseline   0.01     0.07   -0.12                0.14                 0.905
  Localization, 60° (% correct)                            Treatment      -44.45   3.88   -52.15               -36.74               **\<0.0001**
                                                           Year 2         -0.35    3.66   -7.58                6.87                 0.923
                                                           Year 3         1.23     3.40   -5.50                7.96                 0.719
                                                           Year 4         -0.13    2.89   -5.89                5.62                 0.963
                                                           Seq × year 2   -1.37    5.21   -11.67               8.93                 0.793
                                                           Seq × year 3   38.26    4.93   28.52 --             48.01                **\<0.0001**
                                                           Seq × year 4   43.04    4.15   34.78 --             51.29                **\<0.0001**
                                                           CVC baseline   0.14     0.06   0.02 --              0.26                 **0.020**
  CVC score (%)                                            Treatment      -3.72    3.34   -10.33 --            2.88                 0.267
                                                           Year 2         -1.47    3.34   -8.07 --             5.12                 0.659
                                                           Year 3         1.79     3.34   -4.81 --             8.39                 0.536
                                                           Year 4         2.24     3.44   -4.54 --             9.04                 0.514
                                                           Seq × year 2   3.56     4.75   -5.84 --             12.95                0.455
                                                           Seq × year 3   2.14     4.83   -7.40 --             11.69                0.658
                                                           Seq × year 4   -0.13    4.90   -9.81 --             9.55                 0.979
                                                           CVC baseline   0.14     0.04   0.06 --              0.21                 **\<0.001**
                                                                                                                                    

Reference treatment group = simBiCI; reference year = year 1. The final model contained the following variables: time + treatment + time × treatment + baseline CVC phoneme score. In case there was a confounding role for hearing aid use at baseline, this variable was included in the final model as well. SISSS, speech intelligibility-in-noise from spatially separated sources; CVC, consonant vowel consonant; HA, hearing aid; SimBiCI, simultaneous bilateral cochlear implantation; seq, unilateral cochlear implantation/sequential bilateral cochlear implantation group. Bold value means statistical significance.

In the *WPS* of the SISSS test, the UCI/seqBiCI group performed significantly worse over time: 8.70 dB \[3.96 -- 13.44\], *p* \< 0.001. A significant improvement was seen in the UCI/seqBiCI group after receiving CI2 (year 3 (seqBiCI) vs. year 1 (UCI); -6.83 dB \[-11.20 -- -2.45\], *p* = 0.002). In the *BPS* of the SISSS test however, no difference between groups over time was found, yet a significant improvement was seen in the simBiCI group after years 3 and 4 compared to year 1 (year 4 vs. year 1: -2.68 dB \[-4.56 -- -0.80\], *p* = 0.006). HA use at baseline was a significant confounder for the SISSS *BPS*, and therefore the final model was corrected for HA use.

### Localization

The largest differences between groups were seen on the localization tests over time, for example in the 60 degrees configuration: the scores of UCI/seqBiCI were significantly lower (-44.45% \[-52.15 -- -36.74\], *p* \< 0.0001) than the scores of the simBiCI group over time. The UCI/seqBiCI group showed a significant improvement after receiving CI2, which is most evident between year 4 and year 1: 43.04% \[34.78 -- 51.29\], *p* \< 0.0001. The direction and significance of the results of the localization tests in 15 and 30 degrees configurations did not differ from the 60 degrees results.

### Speech Perception in Quiet

The CVC phoneme scores did not differ significantly between groups over time. Also, the course of these scores did not differ significantly between groups and for both groups the scores were stable over time.

Self-Reported Outcomes
----------------------

### Quality of Life Outcomes

[Figure 3](#F3){ref-type="fig"} shows the QoL outcomes preoperatively and during the 4 years of follow-up for both study groups. The EQ-5D, HUI3 and VAS general health scores did not differ significantly between the UCI/seqBiCI and simBiCI group over time ([Table 3](#T3){ref-type="table"}). Also the course of these scores did not differ between groups and for both groups the EQ-5D, HUI3 and VAS general scores remained stable over time.

![Self-reported outcomes on quality of life: a 4-year follow-up. Scores are presented in mean values with an error bar representing the standard deviation. EQ5D, Dutch EuroQol-5D; HUI3, Health Utilities Index 3; VAS, Visual Analog Scale; TTO, Time Trade-off; yr, year; CI, cochlear implant; SimBiCI, simultaneous bilateral cochlear implantation; UCI/seqBiCI, unilateral cochlear implantation/sequential bilateral cochlear implantation group. To improve readability, the results of both groups are presented interleaved, yet follow-up moments were similar in both groups.](fnins-13-00054-g003){#F3}

###### 

Results from a linear regression analysis with an autoregressive residual covariance matrix (generalized estimating equations type) for quality of life outcomes.

               Parameter             Mean     Standard deviation   Lower bound 95% CI   Upper bound 95% CI   *P*-value
  ------------ --------------------- -------- -------------------- -------------------- -------------------- --------------
  EQ-5D        Treatment             0.023    0.031                -0.038               0.083                0.459
               Year 2                0.020    0.030                -0.038               0.079                0.495
               Year 3                0.023    0.028                -0.033               0.079                0.425
               Year 4                0.034    0.025                -0.016               0.083                0.178
               Seq × year 2          -0.009   0.042                -0.093               0.074                0.825
               Seq × year 3          -0.021   0.041                -0.102               0.061                0.618
               Seq × year 4          -0.038   0.036                -0.108               0.033                0.296
               EQ-5D baseline        0.688    0.097                0.493                0.883                **\<0.0001**
  HUI3         Treatment             -0.011   0.050                -0.112               0.089                0.821
               Year 2                0.030    0.046                -0.060               0.120                0.510
               Year 3                0.005    0.042                -0.079               0.088                0.911
               Year 4                -0.022   0.035                -0.090               0.046                0.525
               Seq × year 2          -0.034   0.065                -0.162               0.095                0.603
               Seq × year 3          0.012    0.061                -0.109               0.133                0.848
               Seq × year 4          0.019    0.050                -0.081               0.119                0.711
               HUI3 baseline         0.520    0.164                0.189                0.850                **0.003**
               HA use                -0.172   0.068                -0.308               -0.036               **0.014**
  VAS health   Treatment             0.053    0.040                -0.026               0.132                0.186
               Year 2                0.030    0.035                -0.039               0.099                0.394
               Year 3                0.048    0.032                -0.015               0.112                0.135
               Year 4                -0.012   0.025                -0.062               0.038                0.647
               Seq × year 2          -0.021   0.050                -0.120               0.078                0.672
               Seq × year 3          -0.062   0.046                -0.154               0.029                0.179
               Seq × year 4          0.053    0.037                -0.020               0.126                0.155
               VAS health baseline   0.210    0.077                0.054                0.365                **0.009**
  TTO          Treatment             -0.078   0.031                -0.140               -0.017               **0.013**
               Year 2                -0.002   0.030                -0.061               0.057                0.958
               Year 3                -0.040   0.029                -0.096               0.017                0.169
               Year 4                -0.012   0.024                -0.060               0.036                0.627
               Seq × year 2          -0.005   0.043                -0.089               0.079                0.913
               Seq × year 3          0.084    0.041                0.003                0.165                **0.043**
               Seq × year 4          0.047    0.035                -0.023               0.117                0.183
               VAS health baseline   0.124    0.053                0.017                0.231                **0.025**
                                                                                                             

Reference treatment group = simBiCI. Reference year = year 1. The final model contained the following variables: time + treatment + time × treatment + baseline score. In case there was a confounding role for hearing aid use at baseline, this variable was included in the final model as well. EQ-5D, EuroQol five-dimensional questionnaire; HUI3, the Health Utilities Index mark 3; HA, hearing aid; VAS, Visual Analog Scale on general health; TTO, Time Trade-off; SimBiCI, simultaneous bilateral cochlear implantation; seq, unilateral cochlear implantation/sequential bilateral cochlear implantation group. Bold value means statistical significance.

The TTO score was significantly lower in the UCI/seqBiCI group compared with the simBiCI group over time (-0.078 \[-0.140 -- -0.017\], *p* = 0.017). A significant improvement was seen in the UCI/seqBiCI group after receiving CI2 (year 3 vs. year 1: 0.084 \[0.003- 0.165\], *p* = 0.017). HA use was a significant confounder for the HUI3, and therefore the final model was corrected for HA use.

### Quality of Hearing Outcomes

[Figure 4](#F4){ref-type="fig"} shows the QoH outcomes preoperatively and during the 4 years of follow-up for both study groups. The VAS hearing scores differed significantly between the UCI/seqBiCI and simBiCI group over time (-0.12 \[-0.24 -- -0.01\], *p* = 0.036) ([Table 4](#T4){ref-type="table"}). The course of these scores did not differ between groups. The scores in the UCI/seqBiCI group did not improve significantly after receiving CI2.

![Self-reported outcomes on quality of hearing: a 4-year follow-up. Scores are presented in mean values with an error bar representing the standard deviation. VAS, Visual Analog Scale; SSQ, Speech, Spatial and Qualities Hearing Scale; NCIQ, Nijmegen Cochlear Implant Questionnaire; yr, year; CI, cochlear implant; SimBiCI, simultaneous bilateral cochlear implantation; UCI/seqBiCI, unilateral cochlear implantation/sequential bilateral cochlear implantation group. To improve readability, the results of both groups are presented interleaved, yet follow-up moments were similar in both groups.](fnins-13-00054-g004){#F4}

###### 

Results from a linear regression analysis with an autoregressive residual covariance matrix (generalized estimating equations type) for quality of hearing outcomes.

                     Parameter              Mean      Standard deviation   Lower bound 95% CI   Upper bound 95% CI   *P*-value
  ------------------ ---------------------- --------- -------------------- -------------------- -------------------- --------------
  VAS hearing        Treatment              -0.122    0.057                -0.236               -0.008               **0.036**
                     Year 2                 -0.029    0.052                -0.132               0.074                0.581
                     Year 3                 -0.056    0.048                -0.152               0.040                0.249
                     Year 4                 -0.050    0.039                -0.127               0.027                0.198
                     Seq × year 2           -0.028    0.075                -0.175               0.120                0.710
                     Seq × year 3           0.128     0.070                -0.010               0.266                0.069
                     Seq × year 4           0.107     0.056                -0.005               0.220                0.060
                     VAS hearing baseline   0.201     0.166                -0.132               0.534                0.232
  SSQ1               Treatment              -1.524    0.533                -2.591               -0.458               **0.006**
                     Year 2                 0.161     0.356                -0.542               0.865                0.651
                     Year 3                 -0.063    0.304                -0.665               0.538                0.835
                     Year 4                 -0.183    0.225                -0.630               0.263                0.418
                     Seq × year 2           -0.409    0.508                -1.414               0.597                0.423
                     Seq × year 3           0.831     0.440                -0.041               1.703                0.062
                     Seq × year 4           0.750     0.330                0.096                1.405                **0.025**
                     SSQ1 baseline          0.984     0.220                0.540                1.429                **\<0.0001**
  SSQ2               Treatment              -2.319    0.534                -3.380               -1.259               **\<0.0001**
                     Year 2                 0.460     0.472                -0.473               1.392                0.332
                     Year 3                 0.357     0.426                -0.485               1.200                0.403
                     Year 4                 0.291     0.336                -0.376               0.959                0.389
                     Seq × year 2           -0.999    0.673                -2.328               0.331                0.140
                     Seq × year 3           1.824     0.617                0.604                3.044                **0.004**
                     Seq × year 4           1.543     0.492                0.567                2.520                **0.002**
                     SSQ2 baseline          0.421     0.190                0.039                0.803                **0.032**
  SSQ3               Treatment              -1.623    0.550                -2.723               -0.523               **0.005**
                     Year 2                 -0.288    0.401                -1.081               0.505                0.474
                     Year 3                 -0.087    0.346                -0.772               0.598                0.802
                     Year 4                 -0.229    0.259                -0.743               0.284                0.378
                     Seq × year 2           0.307     0.565                -0.811               1.425                0.588
                     Seq × year 3           1.051     0.494                0.072                2.029                **0.036**
                     Seq × year 4           1.205     0.374                0.463                1.947                **0.002**
                     SSQ3 baseline          0.473     0.161                0.146                0.800                **0.006**
  NCIQ basic         Treatment              -9.620    5.315                -20.218              0.978                0.075
                     Year 2                 -0.263    4.119                -8.406               7.879                0.949
                     Year 3                 -1.316    3.601                -8.441               5.810                0.715
                     Year 4                 -3.863    2.737                -9.292               1.565                0.161
                     Seq × year 2           -5.513    5.881                -17.139              6.112                0.350
                     Seq × year 3           6.352     5.216                -3.970               16.673               0.226
                     Seq × year 4           12.222    4.009                4.273                20.171               **0.003**
                     VAS hearing baseline   -19.889   17.165               -54.545              14.767               0.253
  NCIQ advanced      Treatment              -3.523    6.426                -16.391              9.345                0.586
                     Year 2                 -0.376    4.049                -8.383               7.631                0.926
                     Year 3                 0.764     3.456                -6.076               7.605                0.825
                     Year 4                 -1.034    2.558                -6.106               4.038                0.687
                     Seq × year 2           -3.124    5.787                -14.569              8.322                0.590
                     Seq × year 3           2.485     5.006                -7.425               12.394               0.621
                     Seq × year 4           5.969     3.747                -1.460               13.398               0.114
                     VAS hearing baseline   7.293     21.821               -36.823              51.410               0.740
                     HA use                 -7.025    9.622                -26.485              12.436               0.470
  NCIQ speech        Treatment              0.680     4.581                -8.497               9.857                0.883
                     Year 2                 -0.340    2.785                -5.848               5.168                0.903
                     Year 3                 -0.559    2.368                -5.248               4.129                0.814
                     Year 4                 -1.334    1.746                -4.796               2.128                0.447
                     Seq × year 2           -1.014    3.981                -8.888               6.861                0.799
                     Seq × year 3           -2.524    3.430                -9.316               4.267                0.463
                     Seq × year 4           -1.785    2.558                -6.856               3.286                0.487
                     VAS hearing baseline   -29.738   15.691               -61.456              1.980                0.065
                     HA use                 -4.760    6.921                -18.754              9.234                0.496
  NCIQ self esteem   Treatment              -6.806    4.844                -16.488              2.877                0.165
                     Year 2                 -2.602    3.346                -9.218               4.013                0.438
                     Year 3                 -2.635    2.873                -8.321               3.051                0.361
                     Year 4                 -3.684    2.140                -7.928               0.559                0.088
                     Seq × year 2           0.713     4.781                -8.741               10.167               0.882
                     Seq × year 3           2.618     4.161                -5.618               10.855               0.530
                     Seq × year 4           7.084     3.135                0.869                13.299               **0.026**
                     VAS hearing baseline   10.330    16.380               -22.770              43.429               0.532
  NCIQ activity      Treatment              -6.147    5.595                -17.338              5.044                0.276
                     Year 2                 -0.150    3.796                -7.656               7.357                0.969
                     Year 3                 -0.124    3.252                -6.562               6.313                0.970
                     Year 4                 -2.476    2.417                -7.269               2.317                0.308
                     Seq × year 2           -1.719    5.425                -12.447              9.009                0.752
                     Seq × year 3           6.108     4.411                -3.217               15.433               0.197
                     Seq × year 4           7.802     3.540                0.783                14.822               **0.030**
                     VAS hearing baseline   18.473    19.026               -20.007              56.953               0.338
  NCIQ social        Treatment              -9.264    4.471                -18.201              -0.327               **0.042**
                     Year 2                 -0.804    3.149                -7.031               5.423                0.799
                     Year 3                 0.157     2.711                -5.209               5.523                0.954
                     Year 4                 1.308     2.025                -2.708               5.325                0.520
                     Seq × year 2           0.954     4.499                -7.943               9.850                0.832
                     Seq × year 3           5.790     3.927                -1.982               13.563               0.143
                     Seq × year 4           7.074     2.966                1.191                12.956               **0.019**
                     VAS hearing baseline   15.457    15.016               -14.913              45.827               0.310
                                                                                                                     

Reference treatment group = simBiCI. Reference year = year 1. The final model contained the following variables: time + treatment + time × treatment + baseline score. In case there was a confounding role for hearing aid use at baseline, this variable was included in the final model as well. VAS, Visual Analog Scale on hearing; SSQ, Speech, Spatial and Qualities of Hearing Scale; NCIQ, Nijmegen Cochlear Implant Questionnaire; HA, hearing aid; SimBiCI, simultaneous bilateral cochlear implantation; seq, unilateral cochlear implantation/sequential bilateral cochlear implantation group. Bold value means statistical significance.

The SSQ1, SSQ2 and SSQ3 scores were significantly lower in the UCI/seqBiCI group compared with the simBiCI group over time (most evident for SSQ2: -2.32 \[-3.38 -- -1.26\], *p* ≤ 0.001). A significant improvement was seen in the UCI/seqBiCI group after receiving CI2 for the SSQ1 (year 4 vs. year 1: 0.75 \[0.10 -- 1.41\], *p* = 0.025) and the SSQ 2 and 3 (years 3 and 4 vs. year 1, for example year 3 vs. year 1 for SSQ2: 1.82 \[0.60 -- 3.04\], *p* = 0.004). In the simBiCI group, all SSQ scores remained stable in the 4 years of follow-up.

The social interaction score of the NCIQ was significantly lower in the UCI/seqBiCI group compared with the simBiCI group over time (-9.26 \[-18.20 -- -0.33\], *p* = 0.042). Significant increases in basic sound perception, self-esteem, activity and social interaction scores were seen in the seqBiCI group after receiving CI2 (year 4 vs. year 1, most evident for basic sound perception: 12.22 \[4.27 -- 20.17\], *p* = 0.003). In the simBiCI group, all NCIQ scores remained stable in the 4 years of follow-up.

### Tinnitus Outcomes

[Figure 5](#F5){ref-type="fig"} shows the prevalence of tinnitus burden preoperatively and during the 4 years of follow-up for both study groups. Although the prevalence appears larger in de simBiCI group, the prevalence of tinnitus burden, corrected for baseline prevalence, did not differ significantly between the UCI/seqBiCI and simBiCI group over time. Also the course of tinnitus burden did not differ between groups and for both groups the presence of tinnitus burden remained stable in the 4 years of follow-up ([Table 5](#T5){ref-type="table"}).

![Tinnitus outcomes: a 4-year follow-up. The number of participants with the presence of tinnitus burden. The presence of tinnitus burden is defined as a score higher than 0 on either one of the questionnaires. SimBiCI, simultaneous bilateral cochlear implantation; UCI/seqBiCI, unilateral cochlear implantation/sequential bilateral cochlear implantation group.](fnins-13-00054-g005){#F5}

###### 

Results from a logistic regression analysis with an autoregressive residual covariance matrix (generalized estimating equations type) for the presence of tinnitus burden.

  Parameter           Mean     Standard deviation   Odds ratio   Lower bound 95% CI   Upper bound 95% CI   *P*-value
  ------------------- -------- -------------------- ------------ -------------------- -------------------- -----------
  Treatment           -1.110   0.7918               0.330        0.070                1.556                0.161
  Year 2              -0.278   0.5155               0.758        0.276                2.080                0.590
  Year 3              -0.578   0.6006               0.561        0.173                1.822                0.336
  Year 4              -0.869   0.6452               0.419        0.118                1.485                0.178
  Seq × year 2        0.637    0.6122               1.891        0.569                6.277                0.298
  Seq × year 3        -0.833   0.8966               0.435        0.075                2.520                0.353
  Seq × year 4        0.610    0.7606               1.840        0.414                8.172                0.423
  Tinnitus baseline   2.404    0.7202               11.068       2.698                45.401               **0.001**
                                                                                                           

Reference treatment group = simBiCI. Reference year = year 1. The final model contained the following variables: time + treatment + time × treatment + baseline tinnitus burden presence. SimBiCI, simultaneous bilateral cochlear implantation; seq, unilateral cochlear implantation/sequential bilateral cochlear implantation group. Bold value means statistical significance.

Sensitivity Analysis
--------------------

A sensitivity analysis of the behavioral and self-reported data without participants with missing data revealed no differences regarding direction, effect sizes or significance of the results compared to the primary analysis except for the NCIQ basic sound perception: a significant overall lower NCIQ basic sound perception score was seen in the UCI/seqBiCI group (-11.61, *p*: 0.028). This indicates that missing data in the original analyses did not obscure the results.

Complications
-------------

As shown in [Table 6](#T6){ref-type="table"}, several complications occurred during the 4 years follow-up period. One participant suffered from vertigo 1 year following simBiCI. Electronystagmographic examination was inconclusive, yet vestibular areflexia was excluded as the cause of vertigo. In one participant in the UCI/seqBiCI group, the left CI had to be explanted and re-implanted 4 years after initial implantation. After initial good performance, the left CI became dysfunctional resulting in an increased stimulation level and coexisting facial nerve stimulation. The cause of this failure remained unclear, imaging and integrity tests were normal. One participant in the simBiCI group with a history of panhypopituitarism, hypothyroidism, kidney failure and systemic lupus erythematosus for which corticosteroids were used, suffered from skin flap necrosis after implantation of the left CI. Surgery was needed to close the subsequent skin defect. One participant suffered from a facial nerve palsy 10 days after seqBiCI (House Brackmann grade 3), of unknown origin, possibly due to a viral infection. The palsy improved spontaneously to House Brackmann grade 2. Another participant in the UCI/seqBiCI group suffered from acute otitis media in the secondly implanted ear for which intravenous antibiotic treatment was needed. One participant in the UCI/seqBiCI group perceived extra sound sensations in CI2. In one participant in the UCI/seqBiCI group, local antibiotics had to be administered to treat a skin infection at the implantation site. In both groups, a participant experienced pain at the ear's helix due to pressure of the speech processor, for which a support frame and a body worn speech processor were provided. Although it appears that the complication rate is higher in de UCI/seqBiCI group, this was not statistically supported.

###### 

Complications that occurred in this randomized controlled trial during 4 years of follow-up.

  Adverse events                         SimBiCI   UCI/SeqBiCI   Onset of complication
  -------------------------------------- --------- ------------- -------------------------------------------
  Vertigo/dizziness                      1         0             1 year after simBiCI
  Dysfunction of cochlear implant        1         0             4 years after simBiCI
  Flap necrosis leading to skin defect   0         1             10 months after seqBiCI
  Facial nerve paresis                   0         1             10 days after seqBiCI
  Acute otitis media                     0         1             Two weeks after seqBiCI
  Pain                                   1         1             2 years after simBiCI; 5 months after UCI
  Wound infection                        0         1             Within 1 month after seqBiCI
  Perception of extra sounds             0         1             Within 1 month after seqBiCI
                                                                 

SimBiCI, simultaneous bilateral cochlear implantation; UCI/seqBiCI, unilateral cochlear implantation/sequential bilateral cochlear implantation.

Discussion
==========

Key Findings
------------

The current RCT evaluated the longitudinal behavioral and self-reported outcomes after simBiCI compared with UCI/seqBiCI, with a 2-year inter-implant interval, in adult patients with severe-to-profound bilateral SNHL with marginal benefit of conventional HAs (an aided CVC phoneme score of ≤50% at 65 dB SPL).

Three participants allocated to the UCI/seqBiCI group, did not proceed to seqBiCI. This study showed that speech perception in noise, localization abilities (SISSS WPS, localization) and self-reported results (SSQ 1 and 2) were significantly worse in the UCI/seqBiCI group compared to the simBiCI group over the course of the 4-year follow-up. This is associated with the poorer results obtained by the UCI/seqBiCI group in the first 2 years of unilateral CI use. In the UCI/seqBiCI group, a significant improvement of these scores was seen after receiving CI2. With this improvement, the UCI/seqBiCI participants (with 2 years of bilateral experience) reached the same level as the simBiCI participants at 3 and 4 years of follow-up.

In one of four QoL questionnaires (TTO), a significantly lower utility score was found in the UCI/seqBiCI group compared to the simBiCI group over time. After the participants received CI2 in the seqBiCI group, their TTO results reached to the level of the simBiCI group. The prevalence of tinnitus burden did not differ significantly between both groups over time.

Comparison With Literature and Clinical Implication
---------------------------------------------------

In previous publications from our group, studying the differences between best performing situation with one CI (with or without a contralateral HA) and simBiCI ([@B28]; [@B32]), advantages of simBiCI over UCI on spatial speech perception and localization of sounds were demonstrated behaviorally and subjectively. Corresponding to existing observational studies and our previous article from this RCT, the present study identified that patients after seqBiCI also benefit from receiving a second CI as demonstrated in the spatial speech perception and localization of sounds tasks ([@B25]; [@B29]; [@B33]; [@B21]). Thus, this study shows that after providing deaf patients with one CI, they still benefit from bilateral hearing after sequentially implanting a second CI within an inter-implant interval of 2 years.

No significant differences were found between simBiCI and seqBiCI at 4 years follow-up on behavioral and self-reported outcome measures tested. This finding does not advocate for one of these implantation modalities over the other. Therefore, when considering BiCI, individual factors that might influence the choice for seqBiCI or simBiCI such as for example duration of anesthesia, the intensive rehabilitation, as well as the cost-effectiveness related with each intervention should be taken into account. Yet, delaying implantation of the second ear in our UCI/seqBiCI group did limit hearing in noise and localization capabilities in the 2 years of unilateral CI use. This might have real-life consequences in this timeframe. To our knowledge, the present study is the first to compare outcomes of simBiCI versus seqBiCI in an RCT.

The present findings encourage UCI patients with no or marginal benefit from a contralateral HA to receive a second CI in order to reach improved benefits in speech perception in noise and localization abilities. Thus, there is evidence that implant centers all over the world should consider seqBiCI for all their unilaterally implanted patients with marginal effect or no effect of a contralateral HA. Even though longer duration of inter-implant interval is suggested to cause lesser benefit of CI2 compared to CI1, multiple studies have shown that bilateral results are better than unilateral results ([@B25]; [@B33]). In the present study, the inter-implant interval did not differ between participants in this trial, therefore, the effect of duration of inter-implant interval was not investigated.

It has already been shown that spatial speech perception abilities continue to improve over time for at least 4 years after simBiCI ([@B4]; [@B12]). Longitudinal results of our study are in line with these findings and show an increased performance in the optimal situation of the SISSS in the simBiCI group over time.

In this study, three participants did not proceed to seqBiCI after UCI. Previous data suggested that not all UCI patients proceed to seqBiCI ([@B8]). Therefore, our study finding may be a realistic representation of the actual clinical population at various implant centers. Patients' withdrawal might be influenced by good performance with CI1, yet conversely, bad performance with CI1 could make patients reluctant to proceed to seqBiCI. Of the three participants in the UCI/seqBiCI group who did not proceed to seqBiCI, two were happy with the results after UCI and one participant who was deafened due to rhesus antagonism had such poor results with UCI that improvement after seqBiCI was not expected.

The lack of overall QoL improvement after seqBiCI in three out of four QoL questionnaires corresponds to earlier findings in literature ([@B29]). QoL questionnaires are commonly used in RCTs to perform a cost-utility analysis. As confirmed by the current study, most general health utility instruments are not appropriate to measure changes after cochlear implantation ([@B33]; [@B14]; [@B24]). For example, the EQ-5D and VAS health instruments do not incorporate a hearing element, and are therefore not sensitive to detect change in QoL as a result of cochlear implantation ([@B13]). Moreover, ceiling effects of EQ-5D and TTO were observed, making it even more challenging to detect improvement. Thus, for RCTs on cost-utility analysis, the use of a QoL instrument with a hearing element in cochlear implant studies, for example the HUI3, seems appropriate ([@B4]; [@B13]). As illustrated in [Figure 3](#F3){ref-type="fig"}, HUI3 scores improved after UCI and simBiCI when compared to the situation before implantation. This finding corresponds to previously published data ([@B13]). Nonetheless, to detect smaller differences, such as the additional effect of a second CI in the UCI/seqBiCI group or differences between simBiCI and seqBiCI the HUI3 is not sensitive enough. Compared to QoL questionnaires, QoH questionnaires detected the largest benefit of cochlear implantation, corresponding with previous findings ([@B29]; [@B21]).

The nature of the complications that occurred during our trial were in line with a previous study, in which vertigo, tinnitus and device failure were among the most reported complications after cochlear implantation ([@B6]). Due to the low sample size, the complication rate could not accurately be compared with literature.

Strengths and Limitations
-------------------------

The major strength of the current study is the study design. Since allocation bias is excluded, an RCT provides a high level of evidence (level I). Data were prospectively gathered at the same time points for all participants to ensure consistency in reported outcomes. Furthermore, the study design enabled us to examine multiple outcomes: BiCI versus UCI (and bimodal), simBiCI versus seqBiCI and UCI versus seqBiCI. Another strength is the longitudinal method for data analyses (GEE) since it generates more power to detect differences. These strengths add scientific value to knowledge based on previously published studies.

A possible limitation of this study is the relatively small sample size that made it difficult to detect differences in secondary outcomes. The sample size calculation was based on a power analysis aiming at the primary outcome measure. It was performed under the assumption that the increase in power due to repeated measurements would be sufficient for a time by intervention group interaction in the analysis, effectively describing and testing the intervention effect over time. We decided to calculate the sample size in this manner, since a sample size calculation for repeated measurement requires both accurate means (and standard deviations) of the outcome for each time point as well as the correlation (or covariance) between the measurements at different time points. An accurate estimate for especially the correlations was not available at the moment of conception of the trial in 2008. Longitudinal analyses however, have more power compared to cross-sectional analyses because of the repeated observations at the individual level. This approach may have compensated for the lack of power. Three participants were lost to follow-up. This could have led to a bias in treatment effect. However, the sample size calculation incorporated loss to follow-up up to five participants per group. Moreover, sensitivity analyses showed comparable results to the original analyses regarding effect sizes. The localization abilities were scored as percent correct in three different loudspeaker configurations. In retrospect, presenting these results as a mean error in degrees azimuth would be more valuable than a percent correct score. However, our set-up did not allow us to extract mean error data. HAs were not fitted before every test session. In addition, the noise reduction method may have differed per participant. The rehabilitation was done according to the standards of each CI center. Since we used a block randomization per center, possible differences between centers could not have affected the outcome difference between groups. Another possible limitation is the use of logistic regression instead of linear regression for the tinnitus outcomes. Continuous data provide more information than dichotomous data. We only used the presence of tinnitus and not the THI and TQ scores. Since participants not suffering from tinnitus did not complete the questionnaires, the THI and TQ scores of these patients were lacking. Linear regression analysis with all these missing data would result in biased results.

Conclusion
==========

In this RCT, we evaluated the behavioral and self-reported outcomes after simBiCI compared with UCI/seqBiCI in adult patients with severe-to-profound SNHL with marginal benefit of HAs (aided CVC phoneme score of ≤50%) longitudinally. In the first 2 years of this study, patients after UCI performed significantly worse than patients after simBiCI, on various spatial hearing and localization outcomes. They showed significant improvement after seqBiCI 2 years later and reached the same amount of benefit as the simBiCI group after 4 years of follow-up. Although the interval between sequential implantation was only 2 years, our results show a significant benefit of bilateral implantation both after simultaneous and sequential implantation over UCI with or without a contralateral HA.
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